Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy

Nerve conduction studies (NCS) in diabetic sensorimotor polyneuropathy (DSP) are sensitive, noninvasive, and associated with small coefficients of variation, and correlate well with underlying peripheral nerve morphological change. For these reasons, the current reference standard for DSP involves multivariate instruments that emphasize NCS results. However, the interside symmetry of NCS findings in different stages of DSP are unknown, although requirement for symmetry has been suggested in clinical trials of DSP. We therefore aimed to determine the degree of symmetry of NCS findings in DSP of differing severity stages. A cohort of diabetic patients, including patients without neuropathy and those with mild to severe DSP, was studied. We also studied a series of nondiabetic, healthy subjects. A variation of stratified sampling by means of a clinical neuropathy score ensured that a broad spectrum of neuropathy was studied. A total of 478 subjects was ascertained; patient accrual was discontinued when the smallest clinical group consisted of 50 subjects. Nerve conduction studies were conducted prospectively and in a blinded fashion using surface recordings, averaging for sensory action potentials, control of limb temperature, and standardized techniques. Median and ulnar motor and sensory, peroneal and tibial motor, and sural NCS were performed. Interside symmetry, independent of neuropathy severity, was observed for all investigated nerves, except for the median sensory nerve action potential amplitude, which was lower on the right side. These results confirm that abnormal NCS findings consistent with DSP are reliably symmetrical with the exception of the amplitude of the median sensory nerve action potential. Thus, unilateral evaluation of NCS in DSP is sufficient as a reference standard in clinical trials. We also conclude that great degrees of asymmetry in NCS results are reason to question inclusion of DSP patients in clinical trials.